Dextromethorphan/bupropion (Auvelity) for agitation in Alzheimer's dementia.
The Medical letter on drugs and therapeutics June 22, 2026 DOI: 10.58347/tml.2026.1757b (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | News report Peer reviewed |
|---|---|
| Intervention | Brexpiprazole (Rexulti) |
| Key points | Reports that Auvelity, a fixed-dose combination of dextromethorphan and bupropion, has received FDA approval for agitation associated with Alzheimer's disease dementia, making it the second US-approved product for this indication after brexpiprazole (approved 2023). |
Abstract
Auvelity (Axsome), an extended-release fixed-dose combination of dextromethorphan and bupropion that was approved by the FDA for treatment of major depressive disorder in 2022,1 has now been approved for treatment of agitation associated with dementia due to Alzheimer's disease (AD). It is the second product to be approved in the US for this indication; the oral second-generation antipsychotic drug brexpiprazole (Rexulti) was approved in 2023.